Clinical Trial Update: Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating sintilimab after stereotactic ablation brachytherapy for refractory oligometastatic non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: Tianjin Medical University Second Hospital | Conditions: Oligometastasis, Lung Neoplasms | Phase 2 | Status: UNKNOWN